share_log

Market Whales and Their Recent Bets on MRNA Options

Benzinga ·  Jun 21 01:02

Investors with a lot of money to spend have taken a bullish stance on Moderna (NASDAQ:MRNA).

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 14 uncommon options trades for Moderna.

This isn't normal.

The overall sentiment of these big-money traders is split between 57% bullish and 35%, bearish.

Out of all of the special options we uncovered, 7 are puts, for a total amount of $779,661, and 7 are calls, for a total amount of $313,943.

Projected Price Targets

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $45.0 to $200.0 for Moderna over the recent three months.

Insights into Volume & Open Interest

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 740.31 with a total volume of 1,287.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $45.0 to $200.0 over the last 30 days.

Moderna Option Volume And Open Interest Over Last 30 Days

Options Call Chart

Noteworthy Options Activity:

SymbolPUT/CALLTrade TypeSentimentExp. DateAskBidPriceStrike PriceTotal Trade PriceOpen InterestVolume
MRNAPUTTRADEBULLISH06/20/25$24.6$22.35$23.1$130.00$577.5K350
MRNACALLSWEEPBULLISH09/20/24$11.35$11.25$11.35$140.00$66.5K6610
MRNACALLTRADEBEARISH07/19/24$5.7$5.5$5.5$140.00$60.5K1.9K36
MRNACALLSWEEPBULLISH01/17/25$5.9$5.65$5.85$200.00$58.5K2.4K45
MRNAPUTTRADEBEARISH06/21/24$46.0$42.15$46.0$180.00$46.0K100

About Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Following our analysis of the options activities associated with Moderna, we pivot to a closer look at the company's own performance.

Where Is Moderna Standing Right Now?

  • With a trading volume of 2,071,149, the price of MRNA is up by 0.08%, reaching $133.37.
  • Current RSI values indicate that the stock is may be oversold.
  • Next earnings report is scheduled for 42 days from now.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with Benzinga Pro for real-time alerts.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment